Floatz logo

Balstilimab

Angiosarcoma

Agenus Inc.monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the Angiosarcoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Trilaciclib
QuantumLeap Healthcare Collaborative
Phase 2CCC
Rilvegostomig
QuantumLeap Healthcare Collaborative
Phase 2CCC
Metformin
QuantumLeap Healthcare Collaborative
Phase 2CCC

View all 50 →

Same molecule, other indications

Balstilimab is also rated in:

colorectal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Colorectal AdenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
colorectal carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →